Catalyst
Slingshot members are tracking this event:
Fibrocell (FCSC) to report data on a Phase 1/2 trial to evaluate the safety of FCX-007 in Recessive dystrophic epidermolysis bullosa (RDEB) patients in third quarter of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FCSC | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 26, 2017
Occurred Source:
http://ir.fibrocell.com/phoenix.zhtml?c=253777&p=irol-newsArticle&ID=2302860
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Recessive Dystrophic Epidermolysis Bullosa, Fcx-007
